PBS access criteria for Pulmonary Arterial Hypertension (PAH) medicines have been eased to allow the use of ERA or PDE-5 inhibitor monotherapy in patients with WHO Functional Class (FC) II symptoms. From 1 May 2020 PAH patients with WHO FC II symptoms will be able to access PBS-subsidised monotherapy with endothelin receptor antagonist (ERA) medicines ...
PBS eases restrictions on PAH medicines to include WHO FC II patients
By Michael Woodhead
6 May 2020